Abstract
The objective of the study: to evaluate the commercial XDR test for susceptibility testing of M. tuberculosis to second line anti-tuberculosis drugs in clinical trials and as part of annual professional testing cycles coordinated by the World Health Organization (WHO).Subjects and Methods. Cultures of M. tuberculosis (n = 90) freshly isolated on egg media from clinical samples collected in tuberculosis patients were tested using the Bactec MGIT 960 system and the XDR test under identical conditions. Well-studied strains of M. tuberculosis (n = 216) obtained from the WHO supranational laboratories were repeatedly cultured on Middlebrook 7H10 medium before the study. The drug susceptibility of the cultures was assessed using the XDR test by the nitrate reductase method.Results. A high concurrence (96.7-100%) of the results was shown when testing susceptibility of 90 M. tuberculosis isolates to kanamycin, amikacin, capreomycin and ofloxacin using the XDR test and the Bactec MGIT 960 system with comparable test periods. The use of the XDR test for drug susceptibility testing of 216 M. tuberculosis strains in eleven annual professional testing cycles coordinated by the WHO supranational laboratories provided the results consistent with the consensus one for kanamycin, capreomycin, ofloxacin and amikacin in 98.6, 99.4, 99.4, and 99.0% of cases, respectively. For moxifloxacin and levofloxacin additionally incorporated to the XDR test, completely identical results were obtained.
Highlights
The objective of the study: to evaluate the commercial XDR test for susceptibility testing of M. tuberculosis to second line anti-tuberculosis drugs in clinical trials and as part of annual professional testing cycles coordinated by the World Health Organization (W HO)
Well-studied strains of M. tuberculosis (n = 216) obtained from the W HO supranational laboratories were repeatedly cultured on Middlebrook 7H10 medium before the study
The use of the XDR test for drug susceptibility testing of 216 M. tuberculosis strains in eleven annual professional testing cycles coordinated by the W HO supranational laboratories provided the results consistent with the consensus one for kanamycin, capreomycin, ofloxacin and amikacin in 98.6, 99.4, 99.4, and 99.0% of cases, respectively
Summary
Определение чувствительности M. tuberculosis к противотуберкулезным препаратам второго ряда с использованием XDR-теста в клинических исследованиях и в международных циклах профессионального тестирования. Ш Цель исследования: оценка коммерческого XDR-теста при определении чувствительности M. tuberculosis к противотуберкулезным препа ратам (ПТП) 2-го ряда в клинических исследованиях и в рамках ежегодных циклов профессионального тестирования, координированных Всемирной организацией здравоохранения (ВОЗ). П. Определение чувствительности M. tuberculosis к противо туберкулезным препаратам второго ряда с использованием XDR-теста в клинических исследованиях и в международных циклах професси онального тестирования / / Туберкулёз и болезни лёгких. Testing Susceptibility of M. tuberculosis to Second Line Anti-Tuberculosis Drugs Using the XDR Test in Clinical Trials and International Professional Testing Cycles. The objective of the study: to evaluate the commercial XDR test for susceptibility testing of M. tuberculosis to second line anti-tuberculosis drugs in clinical trials and as part of annual professional testing cycles coordinated by the World Health Organization (W HO)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
